Polyethylene glycol modified interferon therapy

Details Polyethylene glycol modified interferon therapy Polyethylene glycol modified interferon therapy

1997-04-29

1999-06-01

Scheiner, Toni R.

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

424 854, A61K 3821, A61K 3819

Patent

active

059086211

ABSTRACT:
A method comprising administering a PEG.sub.12000 -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.

REFERENCES:
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 5122614 (1992-06-01), Zalipsky
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5539063 (1996-07-01), Hakimi e tal.
patent: 5559213 (1996-09-01), Hakimi et al.
Cottrill et al., 1997, Clinical Onocology, 9/6, (365-380).
Berardi, et al., Fundam. Appl. Toxicol., vol. 30, No. 1, pt. 2, 36, 1996.
Rostaing, et al., Transplantation, vol. 59, No. 10, pp. 1426-1431, May 27, 1995.
Fuertges, et al., 1990, J. of Controlled Release, 11:139-148.
Inada, et al., 1995, Tibtech, 13(3):86-91.
Nieforth, et al., 1996. Clinical Pharmacology & Therapeutics., 59(6):636-46.
Nucci, et al, 1991, Advanced Drug Delivery Reviews, 6:133-151.

Affiliated with

Also associated with

Rating

Polyethylene glycol modified interferon therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polyethylene glycol modified interferon therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyethylene glycol modified interferon therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-953514